Competitive Readiness
Our competitive readiness capabilities have established Deallus as a trusted partner to many of the world’s leading life sciences companies.
Our capability-building, based on the compelling competitor and market insights we unearth, underpins client strategic decision-making, reinforces competitive mindsets and strengthens brand planning processes to enhance competitive readiness across all relevant divisions, functions and geographies.
CI manager training
Integrating competitive intelligence and the management of CI within an organisation
Training the trainer
Developing internal competitive intelligence champions to drive the value of CI throughout the organisation
Building a competitive mindset
Integrating competitive insights into meaningful brand planning
Training field teams
Sales force training centered on developing a competitive mindset and demystifying competitive challenges
The future for telehealth and neuroscience in the US
Catalyzed by Covid-19, the accelerated uptake of virtual services within neuroscience has set in motion a reimagining of future healthcare pathways. The new post-pandemic reality is a hybrid virtual/in-person approach for many neurological and psychiatric conditions - driving rapid regulatory change, reduced delivery costs, and improved patient access.
Disruption has hit pharma
Strategic intelligence for a fiercely competitive marketplace. In the pharmaceutical industry, change has long been known as the only constant. But the last few years have seen the industry challenged and reshaped by drastic internal disruption and external paradigm shifts. Deallus look at key changes in the pharma landscape through the lens of strategic intelligence, and considers how this powerful tool can help pharma stakeholders grasp the full picture of the competitive environment they intend to enter.
CARe To Understand What Will Shape CAR T’s Future?
CAR T-cell therapies space is complex, highly competitive, and quickly evolving. Add the pandemic to the mix and the logistical, reimbursement, and pricing landscape grows even more complicated. In this in-depth paper we research the current state of CAR T-cell therapies and speculate on the factors currently making the largest impact - China, Commercialization, and COVID-19. Read more for a comprehensive, well-researched take on the space.